Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can one pill tame both blood pressure and blood sugar?

NCT ID NCT05573477

Disease control Sponsor: Autotelicbio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether taking two experimental drugs together, ATB-1011 and ATB-1012, can lower both blood pressure and blood sugar in people who have essential hypertension and type 2 diabetes. About 255 participants will receive either the combination, one of the drugs alone, or a placebo. The study measures changes in sitting systolic blood pressure and HbA1c, a marker of long-term blood sugar control, to see if the combination works better than either drug by itself.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two experimental oral tablets, ATB-1011 and ATB-1012, given together
What this could lead to
If the combination works, it could offer a single daily pill that manages both high blood pressure and type 2 diabetes, reducing the burden of taking multiple medications.
What could go wrong
The trial is still in phase 3, and the combination may not prove more effective than each drug alone. Side effects from combining the two drugs are also possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

255 people

The number who actually took part.

Started

Nov 2022

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Those with Primary Hypertension and Type II Diabetes Mellitus (DM) * Those who have been given adequate explanation about the purpose and the details of the clinical trial and have given voluntary, written informed consent * Those who have not taken any antihypertensive agents for ≥2 weeks prior to randomization. * Those who have not taken any oral hypoglycemic agents, except for same dose of metformin (≥1000 mg/day), for ≥8 weeks prior to randomization Exclusion Criteria: * Those with reference arm mean sitting diastolic blood pressure (MSDBP) ≥110 mmHg at screening or at randomization * Those with differences of systolic blood pressure (SBP) ≥ 20 mmHg and diastolic blood pressure (DBP) ≥ 10 mmHg between arms measured 3 consecutive times with ≥2 minutes between each measurement at screening * Those with a history of alcohol or substance abuse * Those who are pregnant or nursing * Those who have received other clinical trial drugs within 12 weeks prior to screening * Those who are deemed ineligible to participate in the clinical trial based on the medical opinion of the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 2 Essential hypertension

Contacts and locations

Locations

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.